Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Gi bleed
1. Department of Gastroenterology and Nutrition
Memorial Sloan-Kettering Cancer Center
September 17, 2015
Management of Acute
Gastrointestinal Bleeding
2. Clinical Case
76F w/ Stage IV NSCLC w/ mets to bone on erlotinib, DVT on
lovenox, diverticulosis, naproxen for back pain, now presents from
SAR w/ back pain and anemia. Hb 10.2 -> 6.5 over 1 week.
PMH
CAD s/p PCI, HTN, HL
Meds
Omeprazole, amlodipine, atorvastatin, candesartan, erlotinib, klonopin,
oxycodone, therapeutic lovenox, senna, colace, fentanyl patch, gabapentin
Allergies
Clindamycin, PCN, sulfa drugs
SH/FH
Denies tobacco, EtOH, illicit drug use
Grandmother w/ colon ca
3. Clinical Case cont.
ROS
+Back pain, no fever/chills, no lightheadedness/dizziness,
denies melena, BRBPR, hematemesis, abdominal pain
PE
Vitals: BP 126/74, HR 93, RR 20, T 36.8C
Gen: NAD
HEENT: OP clear, MMM
Cards: nls1s2, rrr, no mrg
Pulm: cta b/l
Abd: obese, soft, nt, nd, +bs
Rectal: guaiac positive, dark brown stool
Ext: no edema
4. Clinical Case cont.
Labs
Na 128, K 4.6, Cl 94, CO2 26, BUN 12, Cr 0.5, Gluc 106
Nml LFTs
INR 1.1
WBC 9.9, Hb 6.5, Plt 432
FOBT +
Is this patient stable or unstable?
What is the differential diagnosis?
What is the likely source of her anemia?
5. Upper GI Bleed
History
PUD, prior bleeds, EtOH, prior surgical/endoscopic interventions
(marginal ulcers), liver disease (varices), tumor, prior radiation
Meds – NSAIDs, anti-platelets, anticoagulation
ROS – epigastric pain (PUD), retching (Mallory-Weiss tear),
odynophagia/dysphagia (esophageal ulcer)
Physical Exam
Look for evidence of hypovolemia (tachycardia/hypotension)
Abdominal exam
Rectal exam
Guaiac?!
Accurate H&P allows for proper assessment of
bleeding severity, volume status, risk factors,
and triage decision
6. Upper GI Bleed
Clinical Signs
Hematemesis (30%) – vomiting of bright red blood or coffee grounds
50% of pts w/ documented varices bleed from another source
Melena (20%) – black and tarry stools
Caused by enzymatic degradation and oxidation of Fe in Hb during
passage through ileum and colon
Foul smelling, black (not dark)
Make sure pt not on iron or bismuth
Hematochezia (5%) – passage of BRBPR or maroon stools
Usually lower GI or brisk upper GI bleed (≥1L blood loss)
BUN/Cr – usually >30:1 ratio
Secondary to blood protein absorption or pre-renal azotemia
+Guaiac
7. The Role of FOBT
Occult blood loss (by definition, a small amount)
Guaiac relies on peroxidase reaction to identify Hb
Overt blood loss should be obvious from history and exam
Primary role of FOBT is in colon cancer screening
Sensitive, but specificity varies
False-positive results
Dietary peroxidases – rare meats, raw broccoli, turnips,
cauliflower, radishes, cantaloupe
Other – diarrhea/colitis, recent endoscopy, bleeding gums,
hemoptysis, epistaxis, menstruation, hemorrhoids, fissures
FOBT HAS NO SIGNIFICANT INPATIENT
ROLE
13. A score of less than 2 is associated with low risk of further bleeding
or death
14.
15. Initial Management
ABCs
Include orthostatics – indicates ≥15% acute blood loss
IV access
2 large bore IVs (16G or larger), consider central access
Flow proportional to 4th power of catheter radius (you want
short, large bore catheter)
22G 35cc/min
20G 60cc/min
18G 105cc/min
16G 205cc/min
14G 333cc/min
Run fluids wide open (NOT THROUGH PUMP!!!)
16. Initial Management
NPO
STAT labs (CBC, coags, Type & Screen)
Monitor CBC q4-6hrs
Goal Hb >8 (lower goal is better), Plts >50, INR <1.5
Don’t over-transfuse variceal bleeders
No need to wait for labs to hang blood products
Acute bleeders may have normal Hb
Hold anticoagulation
IV PPI (protonix) – 80mg bolus, then 8mg/hr
Consider octreotide if variceal bleed (50mcg bolus, then 50mcg/hr)
Pre-procedure prokinetics-use in pts with high probability of clot or
fresh blood in stomach
ICU consult – recurrent hematemesis, active bleeding,
hemodynamic instability, respiratory distress, comorbidities
17. Acid Suppression w/ PPI
Clot formation requires pH > 6.8
IV H2-blockers raise gastric pH, but tolerance leads to
pH 3-5 within 24hrs
PPI can keep gastric pH >6.8 for over 24hrs
80mg bolus w/ 8mg/hr infusion raises pH >6 in 20 min
PPI before endoscopy accelerates clot formation,
stabilizes existing clots, reduces bleeding, need for
endoscopic therapy, LOS, and initiates healing (Lau et al,
NEJM 2007).
Decrease also seen in rebleeding rates and need for
repeat endoscopy w/ PPI
Laine L and Jensen DM. ACG Practice Guidelines 2012.
18. NG Lavage
No benefit to mortality,
LOS, or tsf requirement
Confirm UGI source
Assess briskness of bleed
Negative lavage
Bleeding stopped
Source distal to closed pylorus
May be feculent material
Irrigate stomach to
facilitate endoscopy
Remove residual blood, gastric
contents
Decrease risk of aspiration
19. Calling a GI Consult
Place order in computer
Know the patient
Know the question you’re asking
Make sure the patient knows GI is being called
20. Management of Upper GI Bleed
EGD – 1st line therapy, can locate and treat source
Non-variceal UGIB >90% success in stopping initial bleed
<20% re-bleed rate, 75% stopped w/ 2nd endoscopy
Tumor bleeding is generally not amenable to endoscopic therapy
Angiography (IR) – actively bleeding (0.5-1cc/min)
Tagged RBC scan (>0.1cc/min)
Surgery
21. Assessment of Upper GI Ulcers
Forrest Classification
Class 1a-Spurting hemorrhage
Class 1b-Oozing hemorrhage
Class IIa-Nonbleeding visible vessel
Class IIb-Adherent clot
Class IIc-Flag pigmented spot
Class III-Clean ulcer base
34. Clinical Case Follow-up
76F w/ Stage IV NSCLC adeno ca w/ mets to bone on
erlotinib, DVT on lovenox, diverticulosis, naproxen
for back pain, now presents from SAR w/ back pain,
guaiac positive brown stools, and anemia. Hb 10.2
6.5 over 1 week.
What’s the diagnosis?
36. Conclusions
Take careful history and physical exam (including rectal)
No role for FOBT in the inpatient setting
ABCs
IV access is critical
IV PPI for UGIB
Consider NG tube placement
Tumor bleeding is not amenable to endoscopic therapy
EGD/colonoscopy is not a risk-free procedure
Active bleeder – call ICU, involve GI ASAP
Up to 60 percent of patients with a history of an upper GI bleed are bleeding from the same lesion
Symptoms that suggest the bleeding is severe include orthostatic dizziness, confusion, angina, severe palpitations, and cold/clammy extremities.
●Varices or portal hypertensive gastropathy in a patient with a history of liver disease or alcohol abuse
●Aorto-enteric fistula in a patient with a history of an abdominal aortic aneurysm or an aortic graft
●Angiodysplasia in a patient with renal disease, aortic stenosis, or hereditary hemorrhagic telangiectasia
●Peptic ulcer disease in a patient with a history of Helicobacter pylori, nonsteroidal anti-inflammatory drug (NSAIDs) use, or smoking
●Malignancy in a patient with a history of smoking, alcohol abuse, or H. pylori infection
●Marginal ulcers (ulcers at an anastomotic site) in a patient with a gastroenteric anastomosis
●Mild to moderate hypovolemia: Resting tachycardia.
●Blood volume loss of at least 15 percent: Orthostatic hypotension (a decrease in the systolic blood pressure of more than 20 mmHg and/or an increase in heart rate of 20 beats per minute when moving from recumbency to standing).
●Blood volume loss of at least 40 percent: Supine hypotension.
Majority of melena originates proximal to Ligament of Treitz although can be from R colon or small bowel.
Melena may be seen with varying degrees of blood loss (as low as 50cc)
Likelihood ratio with patient reported melena 5-6
Melenic stool on exam LR 25
Blood or coffee grounds detected during nasogastric lavage LR 9.6
BUN/Cr >30 LR 7.5
Blood clots in stool lower LR.
Hematochezia is usually associated with lower GI bleeding but can also be seen in brisk upper GI bleeds. Typically patient is orthostatic at that time.
Examination of stool color may provide clue to location of bleeding but not a reliable indicator
Series of 80 patients with severe hematochezia (red/maroon) 74% had colonic lesion, 11 % upper GI lesion, 9% presumed small bowel source, 6% no site was identifiied.
Hemodynamic instability, hemoglobin <10, active bleeding at endoscopy, large ulcer size, ulcer location (posterior duodenal bulb or high lesser gastric curvature are factors associated with rebleeding
Risk assessment of patients is useful to determine which patients are at higher risk of further bleeding or death and may help inform management decisions such as timing of endoscopy, time of discharge, level of care (ward vs. step-down vs. ICU)
Help predict who may be suitable for early hospital discharge or even outpatient care
Decreased resources
Has been shown to predict risk of further bleeding and death in hospitalized patients with UGIB
Also relies on EGD findings
Age <60 0 points, 60-79 1 point, >/=80 2 points
SBP>/=100, pulse <100 0 points, hypotension with systolic BP <100 2 points
No comorbidities 0 points, renal failure/hepatic failure/disseminated cancer 3 points
MW tear but no major lesions or stigmata of recent bleed 0 points, other nonmalignant GI diagnoses 1 point, upper GI tract malignancy 2 points
Recent hemorrhage, none 0, blood found (adherent clot etc) 2
Has been shown to predict the risk of intervention (transfusion vs. endocopy vs. surgery) and death in hospitalized patients
The higher the score, the more likely endoscopic intervention will be required.
Modified Blatchford score is calculated using only BUN, hemoglobin, SBP and pulse. Performs as well as full Blatchford and outperforms Rockall score with regard to predicitng need for clinical intervention, rebleeding and mortality.
AIM65
-Albumin <3
INR>1.5
Altered mental status
SBP<90
Age>65
In validation cohort, mortality rate increased with increasing score
Increasing score also associated with increased LOS and cost
Less is known about rebleeding
Patient s should receive supplemental O2 by NC and NPO
NEJM article by Villaneuva showed that in a RCT of 921 patients with acute UGIB, restrictive transfusion strategy (tranfusion threshold <7g/dl) with target hemoglobin 7-9 significantly decreased 6-week mortality, length of stay and transfusion-related adverse events compared with a liberal transfusion strategy (transfusion threshold <9g/dl with taret hemoglobin 9-11). Excluded all patients presenting with severe hemorrhagic shock (consensus guidelines suggest higher hemoglobin concentrations), patients with ACS, peripheral vasculopathy, stroke, TIA or blood transfusion within 90 days, recent trauma/surgery, a Rockall score of 0 with hemoglobin level higher than 12g/dl, or if attending physician decided that a patient should avoid a specific medical therapy.
Patients in the restrictive group were more likely than those in the liberal group to avoid transfusion (51 vs. 14%) and received fewer units of blood. Mortality was lower in the restrictive strategy group (5 vs. 9%). Patients in the restrictive group were also less likely to have further bleeding or to suffer complications. Among patients with cirrhosis, the risks of death and further bleeding were lower with the restrictive strategy for patients with Child A or B cirrhosis but were similar for patient with Child C cirrhosis. Most of the overall benefit seemed to come from patients with Child A/B cirrhosis
Of note, all patients underwent emergent EGD within 5-6 hours
Prokinetics have been shown to significantly shorten the duration of endoscopy, reduce the need for repeat endoscopy and decrease the need for blood transfusions.
All patients with HD instability (shock, orthostatic hypotension) or active bleeding (hematemesis, BRB per NGT, hematochezia) should be admitted to ICU for resuscitation and observation with BP monitor, EKG, pulse ox.
Other patients can be admitted to regular medical ward, though suggest that all admitted patients with exception of low0risk patients receive EKG monitoring
Intubation in patients with ongoing hematemesis or altered mental status
Initiate blood transfusions if hemoglobin<7g/dl. However, goal to maintain hemoglobin >/=9 for patients at increased risk of adverese events in the setting of signficant anemia, such as those with unstable coronary artery disease
Patients with active bleeding and hypovolemia may require blood transfusion despite normal hemoglobin
Transfusing patients of variceal bleeding to hemoglobin >10 should be avoided.
Provided the aptient is HD stable, urgent endoscopy can usually proceed simultaneously with transfusion and should not be postponed until coagulatopathy is corrected
However, in patients with an INR >/=3 we attempt to correct INR <3 prior to starting an endoscopy with additional FFP beging given after the endoscopy if high-risk stigmata for recurrent bleeding were found or if endoscopic therapy was performed and INR is still >1.5. This approach is based on data that suggest endoscopy is safe in patients who are mildly to moderately anticoagulation (24).
Transfusion of a unit of FFP should be considered after every 4 untis of PRBCs
Platelet transfusions should be considered in patients with life-threatening bleeding who have received antiplatelet agents ie: ASA or plavix. If recent (<1 yr sten) consider discussing with cardiology.
Somatostatin and octerotide have a theoretical benefit in bleeding ulcer disease because they reduce splanchnic blood flow, inhibit gastric acid secretion and may have gastric cytoprotective effects
A meta-analysis of 21 randomized trials that compared PPIs with either placebo or an H2RA for bleeding ulcers (with or without endoscopic therapy) found a significant and consistent reduction in the risk of recurrent bleeding and the need for surgery. However, no effect on mortality.
Meta-analyses of randomized trials have failed to show superior outcomes with high-doses of continuous infusion PPI administration compared with intermittent dosing and using intermittent dosing rather than continuous infusion could decrease resource utilization and cost.
Pantoprazole and esomeprazole are the only IV formulations available in the US and IV lansoprazole has been removed from the world market.
Small studies suggest that intermittent dosing and continuous infusion have similar effects on gastric pH for the first 12 hours after the initial bolus is given.
However, only patients with active bleeding (spurting or oozing), a nonbleeding visible vessel or an adherent clot are generally considered to be at high risk for recurrent bleeding
On the other hand, patients without these high-risk stigmata are considered low risk and do not require endoscopic therapy.
In patients with high-risk stigmata of recent hemorrhage, the twice daily IV PPI may be switched to a standard dose oral PPI 72 hours after endoscopy, provided there is no evidence of recurrent bleeding
However a randomized trial suggested that twice-daily oral dosing may be preferable in patients at high risk of rebleeding. In the trial, patients with Rockall score >/=6 who received a twice-daily oral PPI had a lower rebleeding rate than those who received a once-daily oral PPI
In patients who do not have active bleeding or other high-risk stigmata (ie: visible vessel or adherent clots) can switch to standard-dose oral PPI immediately following endoscopy.
Three types of contact thermal devices:
-Multipolar probes (Gold Probe, quicksilver bipolar probe , BICAP Superconductor)
-Heater probe (Heatprobe)
-Monopolar probe (Coagrasper)
Multipolar probes achieve hemostasis by heating the contacted tissue with electricity that passes between the alternating arrays of positive and negative electrodes located at the tip of the probe. Electrical circuit is completed between two electrodes on the tip of the probe, so circuit is completed locally and no grounding pad is required.
Tissue coagulation occurs at the tip or sides of the multipolar probe when tissue temp reaches 70 degrees celsius. Deep tissue coagulation is restricted because resistance to further coagulation increases exponentially once tissue in contact with probe has been completely dessicated
Coagulation depth can be increased by using large probes, using lower energy levels applied over a longer period of time and using firmer contact (tamponade)
Heater probe: Heater probe has a thermocouple at the tip of probe that heats up to provide tissue coagulation. Because it uses heat transfer across a ceramic tip as its mode of coagulation, the penetration of tissue coagulation is not limited by tissue water, reisstance or dessication, as it is with the multipolar probes. As a result deep coagulation is feasible with the heater probe; this can be dangerous if perforation is a concern such as acutely bleeding lesions with thin bases. Heater probes my be applied perpendicularly to the lesion being treated, which can be a limitation when treating lesions in difficult to access locations.
Monopolar probe: designed for bleeding control are similar to hot biopsy forceps except that the jaws are flat, not curved and cutting and rotatable. Similar to other forms of monopolar technology (such as using a snare with cautery) a grounding pad is required. The tissue for therapy is grasped with the forceps and pulled or tented away from the gastrointestinal wall, which helps limit the depth of cautery.
APC is a non-contact thermal method of hemostasis. It was introduced as an alternative to contact thermal coagulation (heater probe and bipolar cautery) and non-contact technologies (primarily laser). The advantages of APC include ease of application, speedy treatment of multiple lesions in the case of AVM or wide areas (base of resected polyp or tumor bleeding), safety due to reduced depth of penetration and lower cost compared to laser.
Uses argon gas to deliver plasma of evenly distributed thermal energy to a field of tissue adjacent to the probe. A high voltage spark is delivered at the tip of the probe that ionizes the argon gas as it is sprayed from the probe tip in the direction of the target tissue. Argon gas is non-flammable and inexpensive. The ionized gas or plasma then seeks a ground in the nearest tissue, delivering the thermal energy with a depth of penetration of 2-3 mm. Plasma coagulates linearly and tangentially. Good for treating a lesion around a fold and not clearly in view or a lesion that cannot be postioned directly in front of the endoscope.
Evaluation of the small bowel is difficult due to its length, intrperitoneal location and contractility. Methods used to evaluate the small bowel include push enteroscopy, video capsule endoscopy and intraoperative enteroscopy.
Push enteroscopy: only examines small bowel that is 50-150cm distal to the ligament of Treitz
Deep small bowel enterscopy permits visulatization and interventional therapy throughout the small bowel by using insertion techniques that pleat the small bowel onto an overtube. This limits strectching of the small bowel as occurs with push enteroscopy
Options include double balloon enterscopy, single balloon enterscopy, spiral enterscopy